KPIs & Operating Metrics(New)
Growth Metrics

Bristol Myers Squibb (BMY) Income from Continuing Operations (2016 - 2025)

Historic Income from Continuing Operations for Bristol Myers Squibb (BMY) over the last 17 years, with Q4 2025 value amounting to $1.1 billion.

  • Bristol Myers Squibb's Income from Continuing Operations rose 132894.74% to $1.1 billion in Q4 2025 from the same period last year, while for Dec 2025 it was $7.1 billion, marking a year-over-year increase of 17898.8%. This contributed to the annual value of $7.1 billion for FY2025, which is 17898.8% up from last year.
  • Latest data reveals that Bristol Myers Squibb reported Income from Continuing Operations of $1.1 billion as of Q4 2025, which was up 132894.74% from $2.2 billion recorded in Q3 2025.
  • In the past 5 years, Bristol Myers Squibb's Income from Continuing Operations registered a high of $2.5 billion during Q1 2025, and its lowest value of -$11.9 billion during Q1 2024.
  • In the last 5 years, Bristol Myers Squibb's Income from Continuing Operations had a median value of $1.6 billion in 2022 and averaged $976.1 million.
  • Its Income from Continuing Operations has fluctuated over the past 5 years, first surged by 142625.0% in 2021, then tumbled by 62527.57% in 2024.
  • Bristol Myers Squibb's Income from Continuing Operations (Quarter) stood at $2.4 billion in 2021, then fell by 14.63% to $2.0 billion in 2022, then decreased by 12.99% to $1.8 billion in 2023, then tumbled by 95.69% to $76.0 million in 2024, then skyrocketed by 1328.95% to $1.1 billion in 2025.
  • Its Income from Continuing Operations stands at $1.1 billion for Q4 2025, versus $2.2 billion for Q3 2025 and $1.3 billion for Q2 2025.